Cellceutix (OTC: CTIX) is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix’s anti-cancer drug Kevetrin concluded a phase 1 clinical trial, and the company is now preparing its FDA application for a phase 2 ovarian cancer study. Cellceutix is in a phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. The company’s anti-psoriasis drug Prurisol concluded a phase 2 trial, data is still blinded. Cellceutix’s lead antibiotic, Brilacidin, has completed a phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. For more information, visit the company’s website at www.cellceutix.com